Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 4
1990 2
1991 5
1992 3
1993 3
1994 5
1995 4
1996 7
1997 5
1998 7
1999 7
2000 8
2001 13
2002 3
2003 4
2004 1
2006 1
2007 1
2008 1
2010 3
2011 2
2012 3
2013 1
2017 3
2018 3
2019 2
2020 3
2021 4
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: camilleri p. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Among authors: camilleri p. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
Chemotherapy induced Hyponatraemia.
Yeoh KW, Camilleri P, Patel K. Yeoh KW, et al. Among authors: camilleri p. BMJ Case Rep. 2010;2010:bcr05.2009.1920. doi: 10.1136/bcr.05.2009.1920. Epub 2010 Jan 13. BMJ Case Rep. 2010. PMID: 22242071 Free PMC article.
Gemini surfactants: new synthetic vectors for gene transfection.
Kirby AJ, Camilleri P, Engberts JB, Feiters MC, Nolte RJ, Söderman O, Bergsma M, Bell PC, Fielden ML, García Rodríguez CL, Guédat P, Kremer A, McGregor C, Perrin C, Ronsin G, van Eijk MC. Kirby AJ, et al. Among authors: camilleri p. Angew Chem Int Ed Engl. 2003 Apr 4;42(13):1448-57. doi: 10.1002/anie.200201597. Angew Chem Int Ed Engl. 2003. PMID: 12698476 Review.
Orient Expression: Solving the Mystery of Asian Prostate Cancer?
Lamb AD, Bryant RJ, Camilleri P, Hamdy FC. Lamb AD, et al. Among authors: camilleri p. Eur Urol. 2018 Mar;73(3):340-342. doi: 10.1016/j.eururo.2017.10.030. Epub 2017 Nov 11. Eur Urol. 2018. PMID: 29132711 No abstract available.
109 results